表紙
市場調查報告書

細胞因子釋放綜合徵(CRS):流行病學預測(2030)

Cytokine Release Syndrome (CRS) - Epidemiology Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 948138
出版日期 內容資訊 英文 100 Pages
商品交期: 最快1-2個工作天內
價格
細胞因子釋放綜合徵(CRS):流行病學預測(2030) Cytokine Release Syndrome (CRS) - Epidemiology Forecast - 2030
出版日期: 2020年06月01日內容資訊: 英文 100 Pages
簡介
細胞因子釋放綜合徵(CRS)是由各種因素(例如感染和某些藥物)引起的全身性炎症反應,它引起T細胞過度活化,並由T細胞和其他免疫細胞類型引起。引起細胞因子過度分泌。在31個主要國家(美國,德國,法國,意大利,西班牙,英國,日本)進行CAR-T細胞治療後,細胞因子釋放綜合徵的總數(2017年)為31。初步結果表明,在預測期內批准的新CAR-T細胞療法將比現有的Yescarta,Kymriah和其他藥物具有更低的細胞因子釋放綜合徵發生率。

該報告調查了7個主要國家的細胞因子釋放綜合徵(CRS),並提供了有關疾病概述,治療方法,病例和統計信息。

內容

第1章主要見解

第2章CRS概述

第3章疾病的背景和概述

  • 簡介
  • 症狀
  • 原因
  • 風險因素
  • 病理生理學
  • 生物標誌物
  • 感染COVID-19的患者的簡歷
  • 診斷

第4章案例報告

  • 嚴重的細胞因子釋放綜合徵引起紫斑病
  • 使用Nivolumab治療胃癌後的第一例
  • CAR-T細胞療法治療兒童發病

第5章流行病學和患者人數

  • 主要發現
  • 範圍
  • KOL的觀點
  • 多發性骨髓瘤治療範例
  • DLBCL治療範例
  • 所有治療範例
  • CAR-T細胞療法的預測流程
  • CRS流行病學調查方法
  • 在七個主要國家/地區接受CAR-T細胞治療的血液系統惡性腫瘤總數
  • 在7個主要國家/地區接受CAR-T細胞治療後罹患CRS的患者總數

第6章美國流行病學

  • 先決條件和理由
  • 接受CAR-T細胞治療的B細胞NHL患者總數
  • 接受CAR-T細胞治療的急性淋巴細胞白血病(ALL)患者總數
  • 接受CAR-T細胞治療的多發性骨髓瘤(MM)患者總數
  • CAR-T細胞治療後CRS患者總數
  • 按嚴重程度/等級劃分的CRS患者數

第7章歐洲五個國家的流行病學

  • 先決條件和理由
  • 德國
  • 法國
  • 意大利
  • 西班牙
  • 英國

第8章日本流行病學

第9章附錄

  • 參考
  • 報告調查方法

第10章DelveInsight服務內容

第11章免責聲明

第12章關於Delve Insight

目錄
Product Code: DIEI0981

DelveInsight's 'Cytokine Release Syndrome (CRS)-Epidemiology Forecast-2030' report delivers an in-depth understanding of the Cytokine Release Syndrome (CRS), historical and forecasted epidemiology as well as the Cytokine Release Syndrome trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom) and Japan.

Cytokine Release Syndrome (CRS) Understanding

Cytokine release syndrome (CRS) is a systemic inflammatory response that can be triggered by a variety of factors such as infections and certain drugs causing pathologic over-activation of T cells, leading to hypersecretion of cytokines by T cells and other immune cell types.

The symptoms of CRS typically occur within 30-120 min after the infusion has been initiated, and typically the risk is greater during the first infusion. After CAR T-cell therapy, the onset of CRS symptoms seems to be dependent on the administered dose of the active agent of the proliferation kinetics of adoptively transferred cells and ranges from a few minutes up to 14 days but usually occurs within the first week.

Cytokine Release Syndrome (CRS) Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Number of B-cell NHL Patients receiving CART-Therapies, Total Number of Acute lymphoblastic leukemia (ALL) Patients receiving CART-Therapies, Total Number of Multiple Myeloma (MM) Patients receiving CART-Therapies, Total Number of Patients developing Cytokine Release Syndrome (CRS) following CART therapies, and Total Number of Patients Developing Cytokine Release Syndrome (CRS) by Severity/Grade, scenario of CRS in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.

Cytokine Release Syndrome (CRS) Detailed Epidemiology Segmentation

  • Total number of patients who develop Cytokine Release Syndrome following CART therapies in the 7MM were 31 in 2017.
  • Total number of Hematologic malignancies (Includes ALL, B-Cell NHL (DLBCL, FL, PMBCL, etc.), and Multiple Myeloma) patients receiving CART-therapies in the 7MM were observed to be 41 in 2017. These cases will increase in the 7MM throughout the study period, i.e., 2017-2030.
  • Both the therapies Yescarta (Axicabtagene ciloleucel, Kite/Gilead) and Kymriah (Tisagenlecleucel, Novartis) were approved in 2017 in the United States and 2018 in EU-5. Kymriah is the only CAR-T cell therapy, which was approved in Japan in 2019
  • Among the European 5 countries, Germany had the highest population of CRS with 13 cases, followed by France and the United Kingdom with 11 cases respectively. On the other hand, Spain had the lowest population of 6 cases in 2018.
  • Based on the severity criteria, CRS has been classified into Grade 1, 2, 3, and 4. Out of the total population of CRS 31 cases in the US, the highest cases were observed in the grade 1 & 2, and lowest cases accounted in grade 4 in 2017.
  • There is no CAR-T therapy which is approved for Multiple Myeloma (MM) patients. According to DelveInsight, there are around 6-8 emerging CAR-T cell therapies which are expected to launch during forecast period for the treatment of MM and patients will experience cytokine release syndrome. As comparison to Yescarta (Axicabtagene ciloleucel, Kite/Gilead) and Kymriah (Tisagenlecleucel, Novartis), new CAR-T cell therapies that are going to be approved in forecast period, will show lower incidence of Cytokine Release Syndrome based on the preliminary results.

Scope of the Report:

  • The report covers the descriptive overview of Cytokine Release Syndrome (CRS), explaining its causes, signs and symptoms, pathogenesis and currently available therapies.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of Cytokine Release Syndrome (CRS).
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
  • The report provides the segmentation of the disease epidemiology for 7MM by Total Number of B-cell NHL Patients receiving CART-Therapies, Total Number of Acute lymphoblastic leukemia (ALL) Patients receiving CART-Therapies, Total Number of Multiple Myeloma (MM) Patients receiving CART-Therapies, Total Number of Patients developing Cytokine Release Syndrome (CRS) following CART therapies, and Total Number of Patients Developing Cytokine Release Syndrome (CRS) by Severity/Grade.

Report Highlights:

  • 11-Year Forecast of Cytokine Release Syndrome (CRS)
  • 7MM Coverage
  • Total Number of B-cell NHL Patients receiving CART-Therapies
  • Total Number of Acute lymphoblastic leukemia (ALL) Patients receiving CART-Therapies
  • Total Number of Multiple Myeloma (MM) Patients receiving CART-Therapies
  • Total Number of Patients developing Cytokine Release Syndrome (CRS) following CART therapies
  • Total Prevalence of Cytokine Release Syndrome (CRS) based on Risk
  • Total Number of Patients Developing Cytokine Release Syndrome (CRS) by Severity/Grade.

Key Questions Answered

  • What is the disease risk, burden and unmet needs of Cytokine Release Syndrome (CRS)?
  • What is the historical Cytokine Release Syndrome (CRS) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
  • What would be the forecasted patient pool of Cytokine Release Syndrome (CRS) at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Cytokine Release Syndrome (CRS)?
  • Out of the above-mentioned countries, which country would have the highest prevalent population of Cytokine Release Syndrome (CRS) during the forecast period (2020-2030)?

Reasons to buy:

The Cytokine Release Syndrome (CRS) report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the 7MM Cytokine Release Syndrome (CRS) epidemiology forecast.
  • The Cytokine Release Syndrome (CRS) epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
  • The Cytokine Release Syndrome (CRS) epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the eleven-year forecast period using reputable sources.

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Table of Contents

1. Key Insights

2. Executive Summary of Cytokine Release Syndrome (CRS)

3. Disease Background and Overview: Cytokine Release Syndrome (CRS)

  • 3.1. Introduction
  • 3.2. Symptoms
  • 3.3. Causes
  • 3.4. Risk Factors
  • 3.5. Pathophysiology
  • 3.6. Biomarkers
  • 3.7. CRS in patients with COVID-19 infection
  • 3.8. Diagnosis
    • 3.8.1. Grading

4. Case Reports

  • 4.1. Severe cytokine release syndrome resulting in purpura fulminans despite successful response to nivolumab therapy in a patient with pleomorphic carcinoma of the lung: A case report
  • 4.2. The first case of cytokine release syndrome after nivolumab for gastric cancer
  • 4.3. Multimodal therapeutic approach of Cytokine Release Syndrome developing in a child given chimeric antigen receptor-modified T-cell Infusion

5. Epidemiology and Patient Population

  • 5.1. Key Findings
  • 5.2. Scope
  • 5.3. KOL Views
  • 5.4. Multiple Myeloma Treatment Paradigm
  • 5.5. DLBCL Treatment Paradigm
  • 5.6. ALL Treatment Paradigm
  • 5.7. CAR-T Cell Therapies Forecast Flow
  • 5.8. CRS Epidemiology Methodology
  • 5.9. Total Number of Hematologic Malignancies Patients receiving CAR-T Cell Therapies in the 7MM
  • 5.10. Total Number of Patients develop CRS following CAR-T Cell Therapies in the 7MM

6. United States Epidemiology

  • 6.1. Assumptions and Rationale
  • 6.2. Total Number of B-cell NHL Patients receiving CAR-T Cell Therapies in the United States
  • 6.3. Total Number of Acute lymphoblastic leukemia (ALL) Patients receiving CAR-T Cell Therapies in the United States
  • 6.4. Total Number of Multiple Myeloma (MM) Patients receiving CAR-T Cell Therapies in the United States
  • 6.5. Total Number of Patients developing Cytokine Release Syndrome (CRS) following CAR-T Cell Therapies in the United States
  • 6.6. Number of Patients Developing Cytokine Release Syndrome (CRS) by Severity/Grade in the United States

7. EU5 Epidemiology

  • 7.1. Assumptions and Rationale
  • 7.2. Germany Epidemiology
    • 7.2.1. Total Number of B-cell NHL Patients receiving CAR-T Cell Therapies in Germany
    • 7.2.2. Total Number of Acute lymphoblastic leukemia (ALL) Patients receiving CAR-T Cell Therapies in Germany
    • 7.2.3. Total Number of Multiple Myeloma (MM) Patients receiving CAR-T Cell Therapies in Germany
    • 7.2.4. Total Number of Patients developing Cytokine Release Syndrome (CRS) following CAR-T Cell Therapies in Germany
    • 7.2.5. Number of Patients Developing Cytokine Release Syndrome (CRS) by Severity/Grade in Germany
  • 7.3. France Epidemiology
    • 7.3.1. Total Number of B-cell NHL Patients receiving CAR-T Cell Therapies in France
    • 7.3.2. Total Number of Acute lymphoblastic leukemia (ALL) Patients receiving CAR-T Cell Therapies in France
    • 7.3.3. Total Number of Multiple Myeloma (MM) Patients receiving CAR-T Cell Therapies in France
    • 7.3.4. Total Number of Patients developing Cytokine Release Syndrome (CRS) following CAR-T Cell Therapies in France
    • 7.3.5. Number of Patients Developing Cytokine Release Syndrome (CRS) by Severity/Grade in France
  • 7.4. Italy Epidemiology
    • 7.4.1. Total Number of B-cell NHL Patients receiving CAR-T Cell Therapies in Italy
    • 7.4.2. Total Number of Acute lymphoblastic leukemia (ALL) Patients receiving CAR-T Cell Therapies in Italy
    • 7.4.3. Total Number of Multiple Myeloma (MM) Patients receiving CAR-T Cell Therapies in Italy
    • 7.4.4. Total Number of Patients developing Cytokine Release Syndrome (CRS) following CAR-T Cell Therapies in Italy
    • 7.4.5. Number of Patients Developing Cytokine Release Syndrome (CRS) by Severity/Grade in Italy
  • 7.5. Spain Epidemiology
    • 7.5.1. Total Number of B-cell NHL Patients receiving CAR-T Cell Therapies in Spain
    • 7.5.2. Total Number of Acute lymphoblastic leukemia (ALL) Patients receiving CAR-T Cell Therapies in Spain
    • 7.5.3. Total Number of Multiple Myeloma (MM) Patients receiving CAR-T Cell Therapies in Spain
    • 7.5.4. Total Number of Patients developing Cytokine Release Syndrome (CRS) following CAR-T Cell Therapies in Spain
    • 7.5.5. Number of Patients Developing Cytokine Release Syndrome (CRS) by Severity/Grade in Spain
  • 7.6. United Kingdom Epidemiology
    • 7.6.1. Total Number of B-cell NHL Patients receiving CAR-T Cell Therapies in the UK
    • 7.6.2. Total Number of Acute lymphoblastic leukemia (ALL) Patients receiving CAR-T Cell Therapies in the UK
    • 7.6.3. Total Number of Multiple Myeloma (MM) Patients receiving CAR-T Cell Therapies in the UK
    • 7.6.4. Total Number of Patients developing Cytokine Release Syndrome (CRS) following CAR-T Cell Therapies in the UK
    • 7.6.5. Number of Patients Developing Cytokine Release Syndrome (CRS) by Severity/Grade in the United Kingdom

8. Japan Epidemiology

  • 8.1. Assumptions and Rationale
  • 8.2. Total Number of B-cell NHL Patients receiving CAR-T Cell Therapies in Japan
  • 8.3. Total Number of Acute lymphoblastic leukemia (ALL) Patients receiving CAR-T Cell Therapies in Japan
  • 8.4. Total Number of Multiple Myeloma (MM) Patients receiving CAR-T Cell Therapies in Japan
  • 8.5. Total Number of Patients developing Cytokine Release Syndrome (CRS) following CAR-T Cell Therapies in Japan
  • 8.6. Number of Patients Developing Cytokine Release Syndrome (CRS) by Severity/Grade in Japan

9. Appendix

  • 9.1. Bibliography
  • 9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

List of Tables

  • Table 1 Summary of Cytokine Release Syndrome (CRS), Epidemiology and Key Events (2017-2030)
  • Table 2 Clinical risk factors for severe CRS
  • Table 3 Cytokines and Chemokines involved in CRS
  • Table 4 Diagnostic criteria for severe CRS
  • Table 5 Differential diagnoses of CRS-related HLH/MAS
  • Table 6 Published CRS grading systems
  • Table 7 ASTCT CRS Consensus grading
  • Table 8 Total Number of Hematologic malignancies Patients receiving CAR-T Cell Therapies in the 7MM (2017-2030)
  • Table 9 Total Number of Patients develop CRS following CAR-T Cell Therapies in the 7MM (2017-2030)
  • Table 10 Total Number of B-cell NHL Patients receiving CAR-T Cell Therapies in the US (2017-2030)
  • Table 11 Total Number of ALL Patients receiving CAR-T Cell Therapies in the US (2017-2030)
  • Table 12 Total Number of MM Patients receiving CAR-T Cell Therapies in the US (2017-2030)
  • Table 13 Total Number of Patients developing CRS following CAR-T Cell Therapies in the US (2017-2030)
  • Table 14 Number of Patients Developing CRS by Severity/Grade in the US (2017-2030)
  • Table 15 Total Number of B-cell NHL Patients receiving CAR-T Cell Therapies in Germany (2017-2030)
  • Table 16 Total Number of ALL Patients receiving CAR-T Cell Therapies in Germany (2017-2030)
  • Table 17 Total Number of MM Patients receiving CAR-T Cell Therapies in Germany (2017-2030)
  • Table 18 Total Number of Patients developing CRS following CAR-T Cell Therapies in Germany (2017-2030)
  • Table 19 Number of Patients Developing CRS by Severity/Grade in Germany (2017-2030)
  • Table 20 Total Number of B-cell NHL Patients receiving CAR-T Cell Therapies in France (2017-2030)
  • Table 21 Total Number of ALL Patients receiving CAR-T Cell Therapies in France (2017-2030)
  • Table 22 Total Number of MM Patients receiving CAR-T Cell Therapies in France (2017-2030)
  • Table 23 Total Number of Patients developing CRS following CAR-T Cell Therapies in France (2017-2030)
  • Table 24 Number of Patients Developing CRS by Severity/Grade in France (2017-2030)
  • Table 25 Total Number of B-cell NHL Patients receiving CAR-T Cell Therapies in Italy (2017-2030)
  • Table 26 Total Number of ALL Patients receiving CAR-T Cell Therapies in Italy (2017-2030)
  • Table 27 Total Number of MM Patients receiving CAR-T Cell Therapies in Italy (2017-2030)
  • Table 28 Total Number of Patients developing CRS following CAR-T Cell Therapies in Italy (2017-2030)
  • Table 29 Number of Patients Developing CRS by Severity/Grade in Italy (2017-2030)
  • Table 30 Total Number of B-cell NHL Patients receiving CAR-T Cell Therapies in Spain (2017-2030)
  • Table 31 Total Number of ALL Patients receiving CAR-T Cell Therapies in Spain (2017-2030)
  • Table 32 Total Number of MM Patients receiving CAR-T Cell Therapies in Spain (2017-2030)
  • Table 33 Total Number of Patients developing CRS following CAR-T Cell Therapies in Spain (2017-2030)
  • Table 34 Number of Patients Developing CRS by Severity/Grade in Spain (2017-2030)
  • Table 35 Total Number of B-cell NHL Patients receiving CAR-T Cell Therapies in the UK (2017-2030)
  • Table 36 Total Number of ALL Patients receiving CAR-T Cell Therapies in the UK (2017-2030)
  • Table 37 Total Number of MM Patients receiving CAR-T Cell Therapies in the UK (2017-2030)
  • Table 38 Total Number of Patients developing CRS following CAR-T Cell Therapies in the UK (2017-2030)
  • Table 39 Number of Patients Developing CRS by Severity/Grade in the UK (2017-2030)
  • Table 40 Total Number of B-cell NHL Patients receiving CAR-T Cell Therapies in Japan (2017-2030)
  • Table 41 Total Number of ALL Patients receiving CAR-T Cell Therapies in Japan (2017-2030)
  • Table 42 Total Number of MM Patients receiving CAR-T Cell Therapies in Japan (2017-2030)
  • Table 43 Total Number of Patients developing CRS following CAR-T Cell Therapies in Japan (2017-2030)
  • Table 44 Number of Patients Developing CRS by Severity/Grade in Japan (2017-2030)

List of Figures

  • Figure 1 Pathogenesis and management of CRS
  • Figure 2 Clinical presentation of CRS
  • Figure 3 Causes of CRS
  • Figure 4 Mechanism of CAR T-cell therapy and CRS
  • Figure 5 Pathophysiology of CRS
  • Figure 6 Pathways leading to CRS
  • Figure 7 United States KOL Views
  • Figure 8 Europe KOL Views
  • Figure 9 Total Number of Hematologic malignancies Patients receiving CAR-T Cell Therapies in the 7MM (2017-2030)
  • Figure 10 Total Number of Patients develop CRS following CAR-T Cell Therapies in the 7MM (2017-2030)
  • Figure 11 Total Number of B-cell NHL Patients receiving CAR-T Cell Therapies in the US (2017-2030)
  • Figure 12 Total Number of ALL Patients receiving CAR-T Cell Therapies in the US (2017-2030)
  • Figure 13 Total Number of MM Patients receiving CAR-T Cell Therapies in the US (2017-2030)
  • Figure 14 Total Number of Patients developing CRS following CAR-T Cell Therapies in the US (2017-2030)
  • Figure 15 Number of Patients Developing CRS by Severity/Grade in the US (2017-2030)
  • Figure 16 Total Number of B-cell NHL Patients receiving CAR-T Cell Therapies in Germany (2017-2030)
  • Figure 17 Total Number of ALL Patients receiving CAR-T Cell Therapies in Germany (2017-2030)
  • Figure 18 Total Number of MM Patients receiving CAR-T Cell Therapies in Germany (2017-2030)
  • Figure 19 Total Number of Patients developing CRS following CAR-T Cell Therapies in Germany (2017-2030)
  • Figure 20 Number of Patients Developing CRS by Severity/Grade in Germany (2017-2030)
  • Figure 21 Total Number of B-cell NHL Patients receiving CAR-T Cell Therapies in France (2017-2030)
  • Figure 22 Total Number of ALL Patients receiving CAR-T Cell Therapies in France (2017-2030)
  • Figure 23 Total Number of MM Patients receiving CAR-T Cell Therapies in France (2017-2030)
  • Figure 24 Total Number of Patients developing CRS following CAR-T Cell Therapies in France (2017-2030)
  • Figure 25 Number of Patients Developing CRS by Severity/Grade in France (2017-2030)
  • Figure 26 Total Number of B-cell NHL Patients receiving CAR-T Cell Therapies in Italy (2017-2030)
  • Figure 27 Total Number of ALL Patients receiving CAR-T Cell Therapies in Italy (2017-2030)
  • Figure 28 Total Number of MM Patients receiving CAR-T Cell Therapies in Italy (2017-2030)
  • Figure 29 Total Number of Patients developing CRS following CAR-T Cell Therapies in Italy (2017-2030)
  • Figure 30 Number of Patients Developing CRS by Severity/Grade in Italy (2017-2030)
  • Figure 31 Total Number of B-cell NHL Patients receiving CAR-T Cell Therapies in Spain (2017-2030)
  • Figure 32 Total Number of ALL Patients receiving CAR-T Cell Therapies in Spain (2017-2030)
  • Figure 33 Total Number of MM Patients receiving CAR-T Cell Therapies in Spain (2017-2030)
  • Figure 34 Total Number of Patients developing CRS following CAR-T Cell Therapies in Spain (2017-2030)
  • Figure 35 Number of Patients Developing CRS by Severity/Grade in Spain (2017-2030)
  • Figure 36 Total Number of B-cell NHL Patients receiving CAR-T Cell Therapies in the UK (2017-2030)
  • Figure 37 Total Number of ALL Patients receiving CAR-T Cell Therapies in the UK (2017-2030)
  • Figure 38 Total Number of MM Patients receiving CAR-T Cell Therapies in the UK (2017-2030)
  • Figure 39 Total Number of Patients developing CRS following CAR-T Cell Therapies in the UK (2017-2030)
  • Figure 40 Number of Patients Developing CRS by Severity/Grade in the UK (2017-2030)
  • Figure 41 Total Number of B-cell NHL Patients receiving CAR-T Cell Therapies in Japan (2017-2030)
  • Figure 42 Total Number of ALL Patients receiving CAR-T Cell Therapies in Japan (2017-2030)
  • Figure 43 Total Number of MM Patients receiving CAR-T Cell Therapies in Japan (2017-2030)
  • Figure 44 Total Number of Patients developing CRS following CAR-T Cell Therapies in Japan (2017-2030)
  • Figure 45 Number of Patients Developing CRS by Severity/Grade in Japan (2017-2030)
  • Figure 46 SWOT analysis of CRS